What is the role of daclatasvir (Daklinza) in the treatment of hepatitis C virus (HCV) infection?

Updated: Dec 09, 2020
  • Author: David C Wolf, MD, FACP, FACG, AGAF, FAASLD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print


Also in July 2015, daclatasvir (Daklinza), an NS5A inhibitor, received FDA approval for use with sofosbuvir in patients with genotype 3 infection. [24, 25, 26] Daclatasvir was discontinued from the worldwide market 2018 after highly effective, shorter duration HCV regimens emerged.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!